关于我们
成为全球先进的基因工程与再生医学研发企业
我们努力创造一个
让患者无需等待器官移植的新世界
杭州启函生物科技有限公司是一个以基因技术为平台的生物医疗公司。启函生物的使命是创造一个让患者无需等待器官移植的新世界。我们致力于使用世界先进的基因编辑技术来生产出可用于人体移植的安全有效的细胞、组织和器官,解决中国和世界器官移植供体严重短缺的问题。


启函生物由美国科学院和工程院双院院士、哈佛大学George Church教授和合成生物学家杨璐菡博士共同创立。启函生物以研发为基础,以服务患者为己任,以科技创新为核心,立志把先进的科学技术转化为临床安全有效的新型医疗手段。
我们的价值观
服务患者
以患者医疗与康复为已任,以技术创新为先导,站在科研的制高点,脚踏实地、真抓实干,利用基因编辑技术研发出更好的治疗手段和产品,治病救人,造福社会。
勇于担当
面对探索路上的艰难险阻,勇于挑战,求实创新,追求卓越。
团结协作
合作、理解、信任、诚信,启函集合国内外科研、临床和监管方面的优秀团队,通力合作,一起开创一个不需要等待器官移植的新世界。
快乐成长
自豪所从事的艰苦事业,再苦再累也是心甘情愿。长路漫漫,启函关注每一个员工和合作伙伴的身心健康和个人成长,是一个友爱、互助、和谐的大家庭。
董事会
Steven Holtzman
杨璐菡 博士 Luhan Yang Ph.D.
沈南鹏 Neil Shen
夏汲清 博士 Jake Xia Ph.D.
Bob More
Steven Holtzman
董事长 Chairman
Steven Holtzman先生于2016年加入Decibel Therapeutics,担任总裁兼首席执行官。Decibel发现并研发了新的治疗方法来治疗失聪和其他听力障碍。在Decibel之前,他曾担任Biogen企业发展执行副总裁。在Biogen, 他创建并领导项目团队和管理团队通过了八项新药批准。此外,他还领导商业开发和企业并购团队,成功完成大量交易。在Biogen之前,他曾担任癌症药物研发公司Infinity Pharmaceuticals的创始人、首席执行官和董事会主席。此外他还是Millennium Pharmaceuticals (现为Takeda Oncology)的早期领导者和首席商务官,该公司是大规模遗传学和基因组学的先驱。他也是第一家转基因动物公司DNX公司的创始人、董事会成员和执行副总裁。他还是Visterra、Warp Drive和Molecular Partners的董事会成员。同时他也是Humatics, Compugen, 以及Marauder Therapeutics的战略商业顾问。在非营利领域,Steven目前是Berklee音乐学院的董事,此前他曾担任Hastings伦理和生命科学中心董事会副主席。1996年到2001年间,他被总统任命为美国国家生物伦理咨询委员会成员。史蒂夫拥有密歇根州立大学哲学学士学位以及牛津大学Corpus Christi学院哲学硕士学位。

Steven Holtzman joined Decibel Therapeutics as president chief and executive officer in 2016. Decibel discovers and develops novel therapeutic approaches to treat hearing loss and other hearing disorders. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc. At Biogen, Steve created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in largescale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Warp Drive Bio, and Molecular Partners. He serves as a strategic business advisor to Humatics, Compugen, and Marauder Therapeutics. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission. Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.
杨璐菡 博士 Luhan Yang Ph.D.
董事、首席执行官 Director & CEO
杨璐菡博士是启函生物的首席执行官,同时也是美国eGenesis公司的共同创始人及首席科学执行官,杨博士领导两家公司为异种移植的研发做出不懈努力。
2018年被《纽约时报》评选为“当代高瞻远瞩的30位人物”。 2017年被《彭博商业周刊》评选为“全球最有影响50位人物”; 2017年当选达沃斯世界经济论坛“全球青年领袖”;2014年杨博士获选《福布斯》 “全球30位30岁以下科学和医疗领域领军人物”, 并荣获“青年企业家项目”(Young Entrepreneur Initiative)竞赛的桂冠;
杨博士拥有北京大学生物学和心理学双学士学位和哈佛医学院人类生物学和转化医学博士学位。

Dr. Luhan Yang is Chief Executive Office of Qihanbio, co-founder and Chief Scientific Officer of eGenesis. Dr. Yang is currently leading the two companies to make unremitting efforts for research and development of xenotransplantation. She was selected by the New York Times as "30 people with far-sighted vision in the contemporary era"(2018). And honored in the Bloomberg 50 (2017), named “Young Global Leader” by the World Economic Forum (2017), was among “30 Under 30” in Science and Healthcare by Forbes Magazine (2014) and was a laureate of the “Young Entrepreneur Initiative” competition (2014).
Dr. Yang holds B.S. degrees in Biology and Psychology from Peking University and a Ph.D. in Human Biology and Translational Medicine from Harvard Medical School.
沈南鹏 Neil Shen
董事 Director
沈南鹏先生担任红杉资本全球执行合伙人,红杉资本中国基金创始及执行合伙人 ,携程旅行网和如家连锁酒店创始人。他还担任第十三届全国政协委员、现任耶鲁中国中心理事会主席 、中国企业家论坛理事 、中国证券投资基金业协会创业投资基金专业委员会副主席,亚洲协会理事、上海交通大学校董等多项职务。
沈南鹏先生位列美国《福布斯》杂志2018年,2019年“全球最佳创投人”榜首 。所获奖项主要包括:《福布斯》2012-2018年度“全球最佳投资人”榜单中排名最高的华人投资者 、《财富》2015-2017年度“中国最具影响力的50位商界领袖”和 “中国最具影响力的30位投资人”、CB Insights -《纽约时报》2017年度“全球20位顶尖风险投资人” 、《福布斯》百年百位全球最伟大商业思想家等多项大奖 。
沈南鹏先生拥有上海交通大学学士学位以及耶鲁大学硕士学位。

Neil Shen is the Founding & Managing Partner of Sequoia Capital China. He is also a co-founder of Ctrip.com (NASDAQ: CTRP) and Home Inns (NASDAQ: HMIN).
Mr. Shen also serves as a member of the 13th CPPCC National Committee, the Board Chairman of Yale Leadership Center in China, Director of China Entrepreneur Forum (CEF), Vice Chairman of VC Funds Committee of Asset Management Association of China, Trustee of Asia Society, and a Trustee of Shanghai Jiao Tong University.
Mr. Shen topped Forbes magazine's "Best Venture Capital Player in the World" in 2018 and 2019. He was the highest- ranked Chinese investor in Forbes' "World's Best Investor" list from 2012 to 2018. Mr. Shen was selected as Fortune's "China's 50 Most Influential Business Leaders" and "China's 30 Most Influential Investors", named "World's 20 Top Venture Investors" by CB Insights-"New York Times" in 2015-2017 2017, and was among the world's 100 greatest business thinkers by Forbes Magazine.
Mr. Shen received his Master’s degree from the School of Management at Yale University and his Bachelor’s degree from Shanghai Jiao Tong University.
夏汲清 博士 Jake Xia Ph.D.
董事 Director
夏汲清先生是哈佛管理公司的董事总经理。他与团队一起为哈佛大学基金会在各资产类别、战略和区域进行投资。他于2013年6月加入HMC,担任首席风险官,专注于资产配置和投资组合管理。
加入HMC之前,夏先生在摩根士丹利工作17年,担任全球固定收益交易风险主管和纽约全球利率衍生品交易主管,管理全球各地的交易。此前,他是摩根士丹利在日本的固定收益部门的联席主管。在摩根士丹利之前,他曾在纽约所罗门兄弟公司担任固定收入研究副总裁,并在Schlumberger-Doll研究公司担任研究科学家。
夏先生拥有麻省理工学院电气工程和计算机科学博士学位。

Jake Xia is a Managing Director at Harvard Management Company (HMC). He and the team together make investments for Harvard University’s endowment in all asset classes, strategies and regions. He joined HMC in June 2013 as the Chief Risk Officer focusing on asset allocation and portfolio management.
Prior to joining HMC, Mr. Xia spent 17 years at Morgan Stanley, serving as head of global fixed income trading risk and head of global interest rates derivative trading in New York, managing trading groups across the globe. Previously, Mr. Xia was Morgan Stanley’s co-head of fixed income in Japan. Prior to Morgan Stanley, Mr. Xia served as vice president of fixed income research at Salomon Brothers in New York and was a research scientist at Schlumberger-Doll Research.
Mr. Xia holds a PhD in electrical engineering and computer science from Massachusetts Institute of Technology.
Bob More
董事 Director
Bob More先生是Alta Partners公司的董事总经理。此前,他是比尔和梅林达盖茨基金会的高级顾问,并领导了“全球健康风险倡议”。在此之前,他是Frazier Healthcare Ventures和Domain Associates的普通合伙人。
More先生是Kauffman Fellows Program的创始董事会成员,并在“One Revolution”和“Foundation for Innovative New Diagnostics (FIND)”董事会任职。More先生拥有米德尔伯里学院学士学位,以及弗吉尼亚大学达顿商学院硕士学位。

Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” Prior to that, he was a General Partner with Frazier Healthcare Ventures and Domain Associates.
Mr. More was a founding board member of the Kauffman Fellows Program and serves on the boards of One Revolution and the Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.
科研顾问
Dr. GEORGE M. CHURCH
Dr. JAMES F. MARKMANN
Dr. PHILIP O'CONNELL
Dr. GEORGE M. CHURCH
共同创始人,首席科学顾问
乔治·丘奇博士是哈佛医学院的遗传学教授,怀斯研究所的创始成员,同时也是人类基因组计划组织(PGP)的负责人(PGP是世界上唯一的关于人类基因、环境和特征数据的开放式科研项目)。丘奇教授以开拓个人基因组学和合成生物学领域而闻名。他开发了第一个基因组测序方法,并从那时起,为几乎所有的“下一代测序”方法和公司做出了贡献,促使人类全基因组测序成本从30亿美元降至600美元。他的团队发明了人类干细胞基因组CRISPR编辑技术及其他合成生物学技术与应用——包括用于移植器官的新方法、用于衰老逆转的基因疗法,以及用于消除莱姆病和疟疾的基因驱动技术。丘奇教授是IARPA和NIH脑项目的主任,也是美国国立卫生研究院基因组科学卓越中心的主任。他发表了490篇论文,拥有130项专利,也是《再生》一书作者。他获得的荣誉包括富兰克林.鲍尔的科学成就奖、美国国家科学院和工程学院双院院士、时代周刊 “100 位全球最具影响力的人物”,是全球生物技术领域的泰斗。
Dr. JAMES F. MARKMANN
科学顾问
詹姆斯·马克曼博士拥有宾夕法尼亚大学医学院医学博士学位,现任麻省总医院移植外科主任,移植中心临床科主任。他主要进行肝脏、肾脏和胰岛的移植临床工作,研究重点是创造更多可供移植的器官,以及不需要免疫抑制情形下进行移植的方法。他发表了超过300多篇科学论文,15年来持续拥有美国国立卫生研究院课题研究经费。马克曼博士目前是国际胰岛移植协会的当选主席,活跃于许多社团、编辑委员会和组织。
Dr. PHILIP O'CONNELL
科学顾问
菲利普·奥康奈尔博士是国际移植协会前主席,悉尼大学的联合医学教授,美国威斯特米德研究所移植与肾脏研究中心主任,美国卫生与医学研究委员会高级医师。他对移植过程中免疫抑制的临床试验有浓厚的兴趣。奥康奈尔教授是澳大利亚政府器官捐赠工作组的成员,该工作组建议建立澳大利亚器官和组织管理局来监督澳大利亚的器官捐赠。奥康奈尔教授致力于为全世界器官短缺问题建立符合伦理的解决方案,是国际移植协会与世界卫生组织关系的重要纽带。
投资者